Cost ‐effectiveness of empagliflozin in the UK in an EMPA‐REG OUTCOME subgroup with type 2 diabetes and heart failure

ConclusionsThis analysis suggests that adding empagliflozin to SoC in HF patients with T2D constitutes a cost ‐effective use of UK healthcare resources and may provide long‐term health benefits to patients.
Source: ESC Heart Failure - Category: Cardiology Authors: Tags: Original Research Article Source Type: research